The Fatty Liver Treatment Global Market Report 2023, provides comprehensive information on the fatty liver treatment market across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.
Learn More On The Fatty Liver Treatment Market’s Growth:
In accordance with The Business Research Company’s comprehensive analysis presented in the Fatty Liver Treatment Global Market Report for 2023, the trajectory of the global fatty liver treatment market is poised for substantial expansion. Anticipated figures project a notable ascent from $20.83 billion in 2022 to an estimated $22.17 billion in 2023, reflective of a commendable compound annual growth rate (CAGR) of 6.4%. However, the global economic landscape faces the significant disruption emanating from the Russia-Ukraine conflict, posing formidable challenges to the ongoing recovery efforts from the lingering impact of the COVID-19 pandemic.
The geopolitical turmoil has triggered a cascade of repercussions, including the imposition of economic sanctions on multiple nations, a surge in commodity prices, and disruptions in global supply chains. Consequently, the resultant inflationary pressures have reverberated across diverse sectors, influencing both goods and services, while simultaneously inducing an escalation in interest rates that has cast a pervasive impact on markets worldwide. Against this backdrop, the fatty liver treatment market is projected to further burgeon, reaching an impressive $27.98 billion by 2027, propelled by a sustained CAGR of 6%.
Get A Free Sample Of The Report (Includes Graphs And Tables):
A discernible trend within the industry landscape is the prominence of product innovation as a pivotal factor driving market dynamics. Leading entities within the fatty liver treatment sector are strategically engaged in the development of cutting-edge products, a strategic initiative designed to fortify their market standing. An illustrative example of this paradigm shift is exemplified by Akero Therapeutics, a distinguished biotechnology company headquartered in the United States. In March 2023, the company heralded a significant milestone with the announcement of positive Phase II reports pertaining to efruxifermin. This innovative therapeutic agent is specifically formulated for the treatment of non-invasively diagnosed nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Efruxifermin, a differentiated Fc-FGF21 fusion protein, emulates the biological activity of fibroblast growth factor 21 (FGF21), thereby intricately regulating multiple metabolic pathways and cellular processes. Such pioneering advancements underscore the dynamic nature of the fatty liver treatment market, heralding a new era of therapeutic interventions in the pursuit of mitigating hepatic ailments.
The fatty liver treatment market is segmented:
1) By Treatment Type: Anti-Rejection Drugs Or Immunosuppressants, Chemotherapy Drugs, Targeted Therapy, Vaccines, Anti-Viral Drugs
2) By Disease Type: Hepatitis, Liver Cancer, Non-Alcoholic Fatty Liver Disease, Other Diseases
3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users
Top 5 Major Players:
North America was the largest region in the fatty liver treatment market in 2022.
Table of contents:
1. Executive Summary
2. Fatty Liver Treatment Market Characteristics
3. Fatty Liver Treatment Market Trends And Strategies
4. Fatty Liver Treatment Market – Macro Economic Scenario
5. Global Fatty Liver Treatment Market Size and Growth
32. Global Fatty Liver Treatment Market Competitive Benchmarking
33. Global Fatty Liver Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Fatty Liver Treatment Market
35. Fatty Liver Treatment Market Future Outlook and Potential Analysis
List of Tables:
Table 1: Global Historic Market Growth, 2017-2022, $ Billion
Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
Table 3: Global Fatty Liver Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 4: Global Fatty Liver Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 5: Global Fatty Liver Treatment Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 74: Pfizer Inc. Financial Performance
Table 75: Johnson & Johnson Services Inc. Financial Performance
Table 76: Hoffmann La Roche Ltd. Financial Performance
Table 77: AstraZeneca plc Financial Performance
Table 78: Merck & Co. Inc. Financial Performance
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model